In the last 12 months, insiders at Definium Therapeutics made open-market sales of $7 million (225.9K shares) and bought no shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Robert Barrow | Chief Executive Officer | 2,478,230 | 0 | 2,478,230 | 43.1% | 29 Sep, 2026 |
| 2 | Daniel Karlin | Chief Medical Officer | 1,064,708 | 0 | 1,064,708 | 18.5% | 29 Sep, 2026 |
| 3 | Mark Sullivan | Chief Legal Officer | 494,228 | 0 | 494,228 | 8.6% | 29 Sep, 2026 |
| 4 | Brandi Roberts | Chief Financial Officer | 394,528 | 0 | 394,528 | 6.9% | 29 Sep, 2026 |
| 5 | Matthew T. Wiley | Chief Commercial Officer | 359,036 | 0 | 359,036 | 6.2% | 29 Sep, 2026 |
| 6 | Schond L. Greenway | Chief Financial Officer | 295,728 | 0 | 295,728 | 5.1% | 26 Mar, 2024 |
| 7 | Wernli Miri Halperin | Executive President | 287,409 | 0 | 287,409 | 5.0% | 22 Aug, 2024 |
| 8 | Carrie Liao | Chief Accounting Officer | 171,820 | 0 | 171,820 | 3.0% | 26 Mar, 2025 |
| 9 | Cynthia W. Hu | Chief Legal Officersecretary | 80,004 | 0 | 80,004 | 1.4% | 28 Mar, 2022 |
| 10 | Carol A Vallone | Director | 25,170 | 0 | 25,170 | 0.4% | 18 Sep, 2026 |
| 11 | Roger Crystal | Director | 24,289 | 0 | 24,289 | 0.4% | 15 Jun, 2026 |
| 12 | Suzanne Louise Bruhn | Director | 24,289 | 0 | 24,289 | 0.4% | 15 Jun, 2026 |
| 13 | Andreas Krebs | Director | 22,839 | 0 | 22,839 | 0.4% | 18 Sep, 2026 |
| 14 | David W Gryska | Director | 19,900 | 0 | 19,900 | 0.3% | 15 Jun, 2026 |
| 15 | Brigid Makes | Director | 10,581 | 0 | 10,581 | 0.2% | 06 Jun, 2022 |
| 16 | Roger Adsett | Director | 3,555 | 0 | 3,555 | 0.1% | 15 Jun, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 25 Sep, 2026 | Daniel Karlin | Chief Medical Officer | Disposed S | 10,853 | $36.57 | $396.89K | 792,846 | Direct |
| 25 Sep, 2026 | Robert Barrow | Chief Executive Officer | Disposed S | 31,550 | $36.57 | $1.15Mn | 2,213,090 | Direct |
| 25 Sep, 2026 | Brandi Roberts | Chief Financial Officer | Disposed S | 3,377 | $36.57 | $123.50K | 394,528 | Direct |
| 25 Sep, 2026 | Matthew T. Wiley | Chief Commercial Officer | Disposed S | 3,097 | $36.57 | $113.26K | 359,036 | Direct |
| 25 Sep, 2026 | Mark Sullivan | Chief Legal Officer | Disposed S | 14,051 | $36.57 | $513.85K | 494,228 | Direct |
| 18 Sep, 2026 | Carol A Vallone | Director | Acquired M | 1,086 | $35.52 | $38.57K | 22,296 | Direct |
| 18 Sep, 2026 | Andreas Krebs | Director | Acquired M | 1,629 | $35.52 | $57.86K | 21,402 | Direct |
| 18 Sep, 2026 | Andreas Krebs | Director | Disposed M | 1,629 | $0.00 | $0 | 0 | Direct |
| 18 Sep, 2026 | Carol A Vallone | Director | Disposed M | 1,086 | $0.00 | $0 | 0 | Direct |
| 14 Sep, 2026 | Matthew T. Wiley | Chief Commercial Officer | Acquired A | 125,000 | $0.00 | $0 | 362,133 | Direct |
| 14 Sep, 2026 | Daniel Karlin | Chief Medical Officer | Acquired A | 200,000 | $0.00 | $0 | 803,699 | Direct |
| 14 Sep, 2026 | Mark Sullivan | Chief Legal Officer | Acquired A | 125,000 | $0.00 | $0 | 508,279 | Direct |
| 14 Sep, 2026 | Brandi Roberts | Chief Financial Officer | Acquired A | 125,000 | $0.00 | $0 | 397,905 | Direct |
| 14 Sep, 2026 | Robert Barrow | Chief Executive Officer | Acquired A | 750,000 | $0.00 | $0 | 2,244,640 | Direct |
| 02 Sep, 2026 | Robert Barrow | Chief Executive Officer | Acquired A | 40,000 | $0.00 | $0 | 1,513,663 | Direct |
| 03 Sep, 2026 | Robert Barrow | Chief Executive Officer | Disposed S | 19,023 | $37.94 | $721.73K | 1,494,640 | Direct |
| 12 Aug, 2026 | Daniel Karlin | Chief Medical Officer | Acquired A | 100,000 | $0.00 | $0 | 603,282 | Direct |
| 12 Aug, 2026 | Robert Barrow | Chief Executive Officer | Acquired A | 375,000 | $0.00 | $0 | 1,473,246 | Direct |
| 12 Aug, 2026 | Mark Sullivan | Chief Legal Officer | Acquired A | 62,500 | $0.00 | $0 | 383,071 | Direct |
| 12 Aug, 2026 | Matthew T. Wiley | Chief Commercial Officer | Acquired A | 62,500 | $0.00 | $0 | 237,133 | Direct |